Monocyte and macrophage subsets along the continuum to heart failure: Misguided heroes or targetable villains?

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 136-145

  Glezeva, Nadezhda ^a   Horgan, Stephen ^a,b,c   Baugh, John A ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Heart failure; Inflammation; Macrophages; Monocytes; Subsets

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CARDITIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL SUBPOPULATION; CYTOKINE PRODUCTION; DISEASE MODEL; EFFECTOR CELL; EXTRACELLULAR MATRIX; HEART FAILURE; HUMAN; HYPERTENSION; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; MACROPHAGE; MONOCYTE; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TREATMENT PLANNING; WOUND HEALING; ANIMAL; INFLAMMATION; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; INFLAMMATION; MACROPHAGES; MONOCYTES; WOUND HEALING;

EID: 84952667800     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.10.029     Document Type: Review

References (84)

1. Mann D.L. Targeted anticytokine therapy and the failing heart. Am. J. Cardiol. 2005, 95:9C-16C.
2. Gullestad L., Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am. J. Cardiol. 2005, 95:17C-23C.
3. Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2009, 11:119-129.
4. Torre-Amione G. Immune activation in chronic heart failure. Am. J. Cardiol. 2005, 95:3C-8C.
5. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 2002, 91:988-998.
6. Adamopoulos S., Parissis J.T., Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur. J. Heart Fail. 2001, 3:517-526.
7. Santhanakrishnan R., Chong J.P., Ng T.P., Ling L.H., Sim D., Leong K.T., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 2012, 14:1338-1347.
8. van Furth R., Cohn Z.A. The origin and kinetics of mononuclear phagocytes. J. Exp. Med. 1968, 128:415-435.
9. Robbins C.S., Chudnovskiy A., Rauch P.J., Figueiredo J.L., Iwamoto Y., Gorbatov R., et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 2012, 125:364-374.
10. Leuschner F., Rauch P.J., Ueno T., Gorbatov R., Marinelli B., Lee W.W., et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J. Exp. Med. 2012, 209:123-137.
11. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension 2004, 43:739-745.
12. Nicoletti A., Heudes D., Mandet C., Hinglais N., Bariety J., Michel J.B. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc. Res. 1996, 32:1096-1107.
13. Kai H., Kuwahara F., Tokuda K., Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens. Res. 2005, 28:483-490.
14. Xia Y., Lee K., Li N., Corbett D., Mendoza L., Frangogiannis N.G. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol. 2009, 131:471-481.
15. Apostolakis S., Lip G.Y., Shantsila E. Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. Cardiovasc. Res. 2010, 85:649-660.
16. Wrigley B.J., Lip G.Y., Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur. J. Heart Fail. 2011, 13:1161-1171.
17. Wynn T.A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30:245-257.
18. Mentz R.J., Kelly J.P., von Lueder T.G., Voors A.A., Lam C.S., Cowie M.R., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J. Am. Coll. Cardiol. 2014, 64:2281-2293.
19. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011, 11:750-761.
20. Collier P., Watson C.J., Voon V., Phelan D., Jan A., Mak G., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur. J. Heart Fail. 2011, 13:1087-1095.
21. Phelan D., Watson C., Martos R., Collier P., Patle A., Donnelly S., et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS ONE 2012, 7.
22. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
23. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
24. Pamukcu B., Lip G.Y., Devitt A., Griffiths H., Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann. Med. 2010, 42:394-403.
25. Ghattas A., Griffiths H.R., Devitt A., Lip G.Y., Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now?. J. Am. Coll. Cardiol. 2013, 62:1541-1551.
26. Swirski F.K., Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013, 339:161-166.
27. Swirski F.K., Weissleder R., Pittet M.J. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1424-1432.
28. Roberts C.S., Maclean D., Maroko P., Kloner R.A. Relation of early mononuclear and polymorphonuclear cell infiltration to late scar thickness after experimentally induced myocardial infarction in the rat. Basic Res. Cardiol. 1985, 80:202-209.
29. Ono K., Matsumori A., Furukawa Y., Igata H., Shioi T., Matsushima K., et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab. Investig. 1999, 79:195-203.
30. Maekawa Y., Anzai T., Yoshikawa T., Asakura Y., Takahashi T., Ishikawa S., et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J. Am. Coll. Cardiol. 2002, 39:241-246.
31. van der Laan A.M., Ter Horst E.N., Delewi R., Begieneman M.P., Krijnen P.A., Hirsch A., et al. Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur. Heart J. 2014, 35:376-385.
32. Hinglais N., Heudes D., Nicoletti A., Mandet C., Laurent M., Bariety J., et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab. Investig. 1994, 70:286-294.
33. Nicoletti A., Michel J.B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc. Res. 1999, 41:532-543.
34. Campbell S.E., Janicki J.S., Weber K.T. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J. Mol. Cell. Cardiol. 1995, 27:1545-1560.
35. Heymans S., Corsten M.F., Verhesen W., Carai P., van Leeuwen R.E., Custers K., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013, 128:1420-1432.
36. Koren L., Alishekevitz D., Elhanani O., Nevelsky A., Hai T., Kehat I., et al. ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodeling. Int. J. Cardiol. 2015, 198:232-240.
37. Zandbergen H.R., Sharma U.C., Gupta S., Verjans J.W., van den Borne S., Pokharel S., et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. 2009, 14:68-75.
38. Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
39. Shantsila E., Wrigley B., Tapp L., Apostolakis S., Montoro-Garcia S., Drayson M.T., et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J. Thromb. Haemost. 2011, 9:1056-1066.
40. Shantsila E., Lip G.Y. Monocyte diversity in myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:139-142.
41. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 2007, 81:584-592.
42. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
43. Hashimoto D., Chow A., Noizat C., Teo P., Beasley M.B., Leboeuf M., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38:792-804.
44. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
45. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
46. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 2005, 142:481-489.
47. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
48. Pechkovsky D.V., Prasse A., Kollert F., Engel K.M., Dentler J., Luttmann W., et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 2010, 137:89-101.
49. Fallowfield J.A., Mizuno M., Kendall T.J., Constandinou C.M., Benyon R.C., Duffield J.S., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 2007, 178:5288-5295.
50. Higashi-Kuwata N., Jinnin M., Makino T., Fukushima S., Inoue Y., Muchemwa F.C., et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res. Ther. 2010, 12:R128.
51. Li K., Xu W., Guo Q., Jiang Z., Wang P., Yue Y., et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ. Res. 2009, 105:353-364.
52. Nahrendorf M., Swirski F.K., Aikawa E., Stangenberg L., Wurdinger T., Figueiredo J.L., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007, 204:3037-3047.
53. Panizzi P., Swirski F.K., Figueiredo J.L., Waterman P., Sosnovik D.E., Aikawa E., et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J. Am. Coll. Cardiol. 2010, 55:1629-1638.
54. Tsujioka H., Imanishi T., Ikejima H., Kuroi A., Takarada S., Tanimoto T., et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:130-138.
55. Tapp L.D., Shantsila E., Wrigley B.J., Pamukcu B., Lip G.Y. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J. Thromb. Haemost. 2012, 10:1231-1241.
56. Schlitt A., Heine G.H., Blankenberg S., Espinola-Klein C., Dopheide J.F., Bickel C., et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb. Haemost. 2004, 92:419-424.
57. Barisione C., Garibaldi S., Ghigliotti G., Fabbi P., Altieri P., Casale M.C., et al. CD14CD16 monocyte subset levels in heart failure patients. Dis. Markers 2010, 28:115-124.
58. Amir O., Spivak I., Lavi I., Rahat M.A. Changes in the monocytic subsets CD14(dim)CD16(+) and CD14(++)CD16(-) in chronic systolic heart failure patients. Mediat. Inflamm. 2012, 2012:616384.
59. Wrigley B.J., Shantsila E., Tapp L.D., Lip G.Y. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur. J. Clin. Investig. 2013, 43:121-130.
60. Glezeva N., Voon V., Watson C., Horgan S., McDonald K., Ledwidge M., et al. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of m2 macrophage activation in disease pathogenesis. J. Card. Fail. 2015, 21:167-177.
61. Heine G.H., Ulrich C., Seibert E., Seiler S., Marell J., Reichart B., et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int. 2008, 73:622-629.
62. Rogacev K.S., Seiler S., Zawada A.M., Reichart B., Herath E., Roth D., et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur. Heart J. 2011, 32:84-92.
63. Urra X., Villamor N., Amaro S., Gomez-Choco M., Obach V., Oleaga L., et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J. Cereb. Blood Flow Metab. 2009, 29:994-1002.
64. Westermann D., Lindner D., Kasner M., Zietsch C., Savvatis K., Escher F., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 2011, 4:44-52.
65. Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015, 131:550-559.
66. Weisheit C., Zhang Y., Faron A., Kopke O., Weisheit G., Steinstrasser A., et al. Ly6C(low) and not Ly6C(high) macrophages accumulate first in the heart in a model of murine pressure-overload. PLoS ONE 2014, 9.
67. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
68. Frangogiannis N.G., Dewald O., Xia Y., Ren G., Haudek S., Leucker T., et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007, 115:584-592.
69. Ishibashi M., Hiasa K., Zhao Q., Inoue S., Ohtani K., Kitamoto S., et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. 2004, 94:1203-1210.
70. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 2011, 29:1005-1010.
71. Kuwahara F., Kai H., Tokuda K., Niiyama H., Tahara N., Kusaba K., et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003, 41:819-823.
72. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Fine R., Weis S., et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19866-19871.
73. Zamilpa R., Kanakia R., Cigarroa J., Dai Q., Escobar G.P., Martinez H., et al. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1418-H1426.
74. Morimoto H., Takahashi M., Izawa A., Ise H., Hongo M., Kolattukudy P.E., et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ. Res. 2006, 99:891-899.
75. Zamilpa R., Ibarra J., de Castro Bras L.E., Ramirez T.A., Nguyen N., Halade G.V., et al. Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J. Mol. Cell. Cardiol. 2012, 53:599-608.
76. Pawlowska M., Gajda M., Pyka-Fosciak G., Toton-Zuranska J., Niepsuj A., Kus K., et al. The effect of doxycycline on atherogenesis in apoE-knockout mice. J. Physiol. Pharmacol. 2011, 62:247-250.
77. Salminen A., Astrom P., Metso J., Soliymani R., Salo T., Jauhiainen M., et al. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity. FASEB J. 2015, 29:1435-1445.
78. Zeng S., Zhou X., Tu Y., Yao M., Han Z.Q., Gao F., et al. Long-term MMP inhibition by doxycycline exerts divergent effect on ventricular extracellular matrix deposition and systolic performance in stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 2011, 33:316-324.
79. Murray L.A., Chen Q., Kramer M.S., Hesson D.P., Argentieri R.L., Peng X., et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int. J. Biochem. Cell Biol. 2011, 43:154-162.
80. Courties G., Heidt T., Sebas M., Iwamoto Y., Jeon D., Truelove J., et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 2014, 63:1556-1566.
81. Dalmas E., Toubal A., Alzaid F., Blazek K., Eames H.L., Lebozec K., et al. Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat. Med. 2015, 21:610-618.
82. Hu Y., Zhang H., Lu Y., Bai H., Xu Y., Zhu X., et al. Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization. Basic Res. Cardiol. 2011, 106:1311-1328.
83. Ma Y., Halade G.V., Zhang J., Ramirez T.A., Levin D., Voorhees A., et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ. Res. 2013, 112:675-688.
84. Tamaki S., Mano T., Sakata Y., Ohtani T., Takeda Y., Kamimura D., et al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLoS ONE 2013, 8:e68893.